Prospective Analysis Of Nt-Probnp Levels As A Predictor Of Hospital Readmission In Heart Failure Patients: A Single-Center Cohort Study

Abstract

Background: Hospital Readmissions In Heart Failure (HF) Patients Represent A Significant Clinical And Economic Burden. N-Terminal Pro-B-Type Natriuretic Peptide (NT-Probnp) May Serve As A Valuable Biomarker For Predicting Readmission Risk.

Objective: To Evaluate The Prognostic Value Of NT-Probnp Levels Measured At Admission And Discharge In Predicting 30-Day And 90-Day Hospital Readmission Among Heart Failure Patients.

Methods: This Prospective Observational Cohort Study Enrolled 60 Patients Hospitalized With Acute Heart Failure At Government Medical College Amritsar Between July 2024 And December 2024. NT-Probnp Levels Were Measured At Admission And Discharge. Primary Endpoint Was All-Cause Readmission At 30 Days; Secondary Endpoints Included HF-Specific Readmission At 30 And 90 Days, And All-Cause Mortality.

Results: Mean Age Was 68.4 ± 12.7 Years; 58% Were Male. Median Admission NT-Probnp Was 3,245 Pg/Ml (IQR: 1,876-5,432). Thirty-Day Readmission Rate Was 23.3% (N=14). Discharge NT-Probnp>2,000 Pg/Ml Was The Strongest Predictor Of 30-Day Readmission (HR 2.84, 95% CI: 1.67-4.83, P<0.001). NT-Probnp Reduction <30% During Hospitalization Was Associated With Increased Readmission Risk (HR 2.12, 95% CI: 1.34-3.35, P=0.001). The Optimal Cutoff For Discharge NT-Probnp Was 1,985 Pg/Ml (Sensitivity 74%, Specificity 68%, AUC 0.73).

Conclusions: NT-Probnp Levels At Discharge And Percentage Reduction During Hospitalization Are Significant Predictors Of Readmission In Heart Failure Patients. These Findings Support The Use Of NT-Probnp For Risk Stratification And Discharge Planning.